Junshi Biosciences announced positive Phase 3 results for its anti-IL-17A monoclonal antibody JS005 in treating moderate-to-severe plaque psoriasis among Chinese patients, achieving primary and secondary endpoints with significant clinical benefit and favorable safety. Led by Peking University researchers, the trial results represent a meaningful advance amidst limited traditional treatment options in China. Junshi plans to pursue regulatory approval and expand indications with ongoing studies targeting ankylosing spondylitis, bolstering its autoimmune portfolio alongside PD-1 checkpoint inhibitors.